Pei, Jing

A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity

Khan, S., Zhang, X., Lv, D., Zhang, Q., He, Y., Zhang, P., Liu, X., Thummuri, D., Yuan, Y., Wiegand, J. S., et al. (2019) · Nature Medicine

Protein Degradation and InhibitorsCell death mechanisms and regulation

Cited by 688

Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity,

Lv, D., Pal, P., Liu, X., Jia, Y., Thummuri, D., Zhang, P., Hu, W., Pei, J., Zhang, Q., Zhou, S., et al. (2021) · Nature Communications

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 158

Discovery of IAP-recruiting BCL-XL PROTACs as potent degraders across multiple cancer cell lines

Zhang, X., He, Y., Zhang, P., Budamagunta, V., Lv, D., Thummuri, D., Yang, Y., Pei, J., Yuan, Y., Zhou, D., et al. (2020) · European Journal of Medicinal Chemistry

Protein Degradation and InhibitorsCell death mechanisms and regulation

Cited by 71